The week of 4-8 November 2024 is set aside to celebrate the work of nearly 1 million trustees volunteering for charities across the UK. Trustees are individuals responsible for the
Guilt – Helen Stewart
As mothers, we have a strong biological urge to protect our offspring. To protect them and keep them safe from harm. That urge starts at their birth and continues as
My cost of living crisis – Helen Crawford
I was just 39 years old, a mother of three young girls, facing a life expectancy of two to three years post-secondary breast cancer diagnosis. My chance to see my
Tassia Haines
We are heartbroken to share the news that Tassia Haines has died. A member of METUPUK and our Executive Lead for Wales, Tass had been a significant campaigner for MBC
Asha Umrawsingh
METUPUK are saddened by the news that one of our members and friend Asha Umrawsingh has died. Asha’s diagnosis and access to treatment was a roller coaster of how strict
PARP inhibitor Talazoparib recommended by NICE for the treatment of hereditary BRCA mutated metastatic breast cancer
METUPUK are delighted by the National Institute of Clinical Excellence (NICE) decision to recommend Talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with germline
NICE Methodology Roundtable Discussion
In November 2023 METUPUK trustee Madeleine Meynell was a panel member at the event Optimising NICE outcomes: Policy roundtable on the evolution of NICE methodology and how patient organisations can
Mindfulness and Metastatic Breast Cancer at Christmas
Living with an incurable form of cancer presents lots of physical, emotional and mental challenges not least of which are the expectations and pressures associated with annual celebrations and milestones;
Dear Beth…
Hi Beth, it’s Kat here, We never met but your name is talked about so often. Whether it be an amazing thing you did, a funny story, your intellect on
NICE invites comments from the public on the draft guidance to not recommend the parp inhibitor talazoparib
METUPUK are disappointed by the National Institute of Clinical Excellence (NICE) decision to not recommend talazoparib (Talzenna ®, Pfizer Ltd.) for treating HER2-negative, locally advanced or metastatic breast cancer with